Strategy

Specialty drug firm Norgine splits from the British pharma association due to a growing rift about pricing. A "war of the roses" is escalating between Big Pharma and smaller drug manufacturers; Norgine could be the first casualty.

The pharma giant just announced major plans to break up its R&D divisions into smaller units targeting areas of growth. Marketing will be part of the restructuring plan, and there is good news: No new layoffs.

Manufacturers overpay PBMs millions of dollars each year in rebates overpayments. Here's how to stop the leakage.

Japan is playing a game of catch-up, dropping big cash on biotechs and risky acquisitions. But with patents expiring and sales falling, can they really pay their way to global success?

Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works.

Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug.

Glaxo's cancer departments will be consolidated into one big division encompassing discovery, research, and trials. The move is expected to cost some jobs, but GSK hopes it will strengthen synergy within its R&D unit.

A new study from the NIMH shows that next-generation treatments for schizophrenia might not be any better than older, first generation drugs-and in some cases might be worst.

A new study shows that while the combo drug decreases the chance of coronary artery disease, it doesn't work as well in slowing down aortic valve disease. So why is all the focus on cancer deaths?

The Belgium-based drug maker is terminating 2,000 jobs and rebranding itself as a biopharm with a focus on CNS and immunology drugs. Pharm Exec gave UCB a call to find out more.

Pharm Exec's 7th annual review of the top companies. We slice and dice the numbers to see who's the best a what. (pdf)

Outsourcing saves money-except when it doesn't. Here's how to decide what to do.

The case for preemption gets shot down in Texas, but holds up in yet another Medtronic suit in Minnesota.

Margaret McGlynn, Merck's head of vaccines, expounded yesterday on the state of the company's vaccine program, including campaign strategies, product development, and a new reimbursement program for doctors.

A new study reports that more than 27 percent of Americans are not being treated for HIV because they fear adverse reactions to the drugs. Pharm Exec talked to the doctors in charge of the survey to learn more.

The industry is a-changing. Here are eight seminal events that describe how.

An answer to your question: What does the Part D coverage gap do to drug sales?

Glaxo launched a YouTube page targeting potential employees through YouTube. One video in particular features CEO Andrew Witty talking about his adventures in GSK. Is this the future of recruitment?

A new global CEO study examines what near- and long-term changes pharma leaders expect to face and in what areas they are planning to focus their attention. Key focus areas: global business design and new markets.

A look at some of the court cases that could actually change the pharma playing field

Could gene silencing be the next great innovation in drug development? Some biotechs are betting on it.

Merck bolsters vaccine making division with the addition of 400 new employees to fill its new manufacturing plant.

French drugmaker to cut 800 jobs, joining the long list of companies restructuring to make ends meet.

In our first ever Emerging Leadership Awards, we profile 45 talented young professionals who will lead pharma into the next generation

An industry legend weighs in on leadership, research, and sales models. Q&A with outgoing Wyeth Chairman Bob Essner

Second annual Not Big Pharma audit gives equal time to the little guys. Who's got the Midas touch?

In a win-win situation for both companies, Merck gets access to one of the hottest generics firms in the world while Ranbaxy gets a chance to hang with the big boys.

Marketers and sales reps feel the brunt of faltering Procrit sales as J&J consolidates its biologics divisions.

Your guide to the world's top 50 pharma companies. The giants may be struggling, but even in a tough year, the industry's most successful companies know how to hit the bullseye.

In these cost cutting times, no drugmaker can afford to keep shoveling money down the Rebate Black Hole. Here's how to optimize your ROI and push back against the growing pressure of third-party rebates